title: Prospective study of chemotherapy in patients with metastatic gastrinoma.
abstract: Ten consecutive patients with metastatic gastrinoma that increased in size over time were studied prospectively during treatment with monthly cycles of streptozotocin (3 g/m2), 5-fluorouracil (1.2 g/m2), and adriamycin (40 mg/m2) to determine the response rate and time-courses of changes during chemotherapy and to assess various methods of evaluating the effect of chemotherapy. Forty percent of patients demonstrated an initial objective response (greater than or equal to 25% decrease in tumor size with no new lesions) and 60% failed chemotherapy (greater than or equal to 25% increase in tumor size or appearance of new lesions). The mean dose of streptozotocin was 27 g/m2 with objective responses occurring at 3.7 +/- 0.7 mo and failures at 4.5 +/- 0.7 mo. Responses lasted 9.7 +/- 2.8 cycles and no complete responses occurred. Survival was not significantly different in responders versus nonresponders (26 +/- 11 vs. 15 +/- 4.8 mo, p greater than 0.1). Changes in serum gastrin concentration, basal acid output, or sensitivity to a given dose of histamine H2-receptor antagonist did not reflect changes in tumor size. Computed tomography and angiography were the best methods to assess changes in tumor size during chemotherapy, whereas liver-spleen scan and ultrasound were relatively insensitive. All patients developed side effects with chemotherapy: 100% had vomiting, 80% alopecia, 40% transient proteinuria, and 20% leukopenia. The present results indicate that chemotherapy with streptozotocin, 5-fluorouracil, and adriamycin is much less effective in patients with extensive metastatic gastrinoma than previously reported. Computed tomography scanning is the method of choice to assess changes in tumor size. Changes in serum gastrin concentration, acid secretion, or tumor size assessed by liver-spleen scan or ultrasound are not sensitive indicators of the tumor response during chemotherapy.
authors.affiliation: Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
authors.forename: T
authors.initials: T
authors.lastname: von Schrenck
authors.forename: J M
authors.initials: JM
authors.lastname: Howard
authors.forename: J L
authors.initials: JL
authors.lastname: Doppman
authors.forename: J A
authors.initials: JA
authors.lastname: Norton
authors.forename: P N
authors.initials: PN
authors.lastname: Maton
authors.forename: F P
authors.initials: FP
authors.lastname: Smith
authors.forename: R
authors.initials: R
authors.lastname: Vinayek
authors.forename: H
authors.initials: H
authors.lastname: Frucht
authors.forename: S A
authors.initials: SA
authors.lastname: Wank
authors.forename: J D
authors.initials: JD
authors.lastname: Gardner
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005744:Gastric Acid / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013311:Streptozocin / Q000008:administration & dosage; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000556:secondary*
chemical_list: D005755:Gastrins; D013311:Streptozocin; D004317:Doxorubicin; D005472:Fluorouracil